Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
JOINN LABORATORIES (CHINA) CO., LTD.
北 京 昭 衍 新 藥 研 究 中 心 股 份 有 限 公 司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 6127)
2021 FIRST QUARTERLY REPORT
This announcement is made pursuant to Rule 13.09(2) and Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).
The following is the first quarterly report of JOINN Laboratories (China) Co., Ltd. (the "Company", together with its subsidiaries, collectively the "Group") for financial year 2021 (the "2021 First Quarterly Report"). This announcement and the accompanying financial statements are originally prepared in Chinese and published in both English and Chinese. If there is any inconsistency or conflict between the Chinese and English versions, the Chinese version shall prevail.
Shareholders of the Company and public investors should note that the financial report therein is prepared in accordance with the PRC Accounting Standards for Business Enterprises and has not been audited.
By order of the Board
JOINN Laboratories (China) Co., Ltd.
Feng Yuxia
Chairperson
Hong Kong, Thursday, April 29, 2021
As at the date of this announcement, the Board comprises Ms. FENG Yuxia as the Chairperson and executive Director, Mr. ZUO Conglin, Mr. GAO Dapeng, Ms. SUN Yunxia, Dr. YAO Dalin as executive Directors, Mr. GU Xiaolei as a non-executive Director, and Mr. SUN Mingcheng, Dr. ZHAI Yonggong, Mr. OU Xiaojie and Mr. ZHANG Fan as independent non-executive Directors.
- 1 -
- Important Notice
- The Board of Directors (the "Board"), the Supervisory Committee and the Directors, Supervisors and Senior Management of the Company warrant the truthfulness, accuracy and completeness of the contents of the Quarterly Report and that there are no false information, misleading statements or material omissions in the quarterly report, and shall assume several and joint legal responsibilities.
- All Directors of the Company attended the Board meeting to review the quarterly report.
- Feng Yuxia, the legal representative of the Company, Yu Aishui, the chief financial officer and Yu Aishui, the director of the accounting department warrant the truthfulness, accuracy and completeness of the financial statements in this quarterly report.
- The First Quarterly Report of the Company has not been audited.
II. | Company Profile | ||||
2.1 | Major financial data | ||||
Unit: RMB | Currency: RMB | ||||
As at the end of | Increase/ | ||||
the Reporting | As at the end of | decrease | |||
Period | the previous year | (%) | |||
Total assets | 7,633,988,121.93 | 2,107,821,636.06 | 262.17 | ||
Net assets attributable to | |||||
shareholders of the Company | 6,597,313,422.62 | 1,224,899,092.29 | 438.60 | ||
From the | From the | ||||
beginning of | beginning of | ||||
the year to | the previous year | ||||
the end of | to the end of | Increase/ | |||
the Reporting | the last reporting | decrease | |||
Period | period | (%) | |||
Net cash flow from operating | |||||
activities | 34,482,082.76 | 34,315,183.44 | 0.49 | ||
- 2 -
From the | From the | ||
beginning of | beginning of | ||
the year to | the previous year | ||
the end of | to the end of | Increase/ | |
the Reporting | the last reporting | decrease | |
Period | period | (%) | |
Revenue | 200,992,535.41 | 154,713,623.00 | 29.91 |
Net profit attributable to | |||
shareholders of the Company | 93,357,265.26 | 19,127,779.80 | 388.07 |
Net profit attributable to | |||
shareholders of the Company | |||
after deducting non-recurring | |||
gain or loss items | 79,434,821.17 | 14,761,153.59 | 438.13 |
Weighted average return on | Increased by 0.80 | ||
equity (%) | 3.08 | 2.28 | percentage point |
Basic earnings per share (RMB | |||
per share) | 0.39 | 0.09 | 333.33 |
Diluted earnings per share | |||
(RMB per share) | 0.38 | 0.09 | 322.22 |
Note: The Company completed its listing of H shares on February 26, 2021 and raised proceeds of HK$6.373 billion (including the exercise of over-allotment options). The effect on the net profit of the exchange gain incurred during the current period was RMB57,887,235.16. Excluding such effect, the growth rate of the net profit attributable to the shareholders of the listed company was 85.44% and the growth rate of the net profit attributable to the shareholders of the listed company (excluding non-recurring gains or losses) was 45.97%.
- 3 -
Non-recurring gain on loss items and amounts
- Applicable □ Not applicable
Unit: RMB Currency: RMB | ||
Amount for | ||
Item | the Reporting | |
Period | Description | |
Gain or loss on disposal of non-current | ||
assets | -4,468.47 | |
Tax refunds or relief subject to ultra vires | ||
or without official approval | ||
Government grants included in profit or | ||
loss of the current period (except for | ||
those closely related to the Company's | ||
normal operation and which were granted | ||
on a recurring basis subject to certain | ||
amount or volume upon fulfilment of | ||
specific standards in compliance with the | ||
government policies and regulations) | 17,220,308.10 | |
Capital occupancy fee from non-financial | ||
enterprises recognized through profit or | ||
loss for the period | ||
Gain from the difference between the | ||
cost of investment on the subsidiaries, | ||
associates and joint ventures and the | ||
shared fair value of identifiable net assets | ||
of the investee | ||
Profit or loss from exchange of non- | ||
monetary assets | ||
Gain or loss from entrusted investments or | ||
assets management | ||
Provision for impairment of assets due to | ||
force majeure such as natural disasters | ||
Profit or loss from debt restructuring | ||
Corporate restructuring costs, such as | ||
employee placement expenses and | ||
integration costs | ||
Profit or loss representing the difference | ||
between the unfair transaction | ||
consideration and the fair value of the | ||
transaction | ||
- 4 -
Amount for | ||
Item | the Reporting | |
Period | Description | |
Net profit or loss of subsidiaries resulting | ||
from merger of enterprises under | ||
common control from the beginning of | ||
the current period to the date of merger | ||
Profit or loss from contingencies not | ||
related to the ordinary operations of the | ||
Company | ||
Investment incomes from holding financial | ||
assets available-for-trading, derivative | ||
financial assets, changes in the fair | ||
value from trading financial liabilities | ||
and derivative financial liabilities, | ||
disposals of trading financial assets, | ||
derivative financial assets, trading | ||
financial liabilities, derivative financial | ||
liabilities and investment in other equity | ||
instruments, except for effective hedging | ||
business related to normal operating of | ||
the Company | 1,427,975.33 | |
Reversal of the provisions for impairment | ||
of receivables and contract assets subject | ||
to impairment test separately | ||
Profit or loss from external entrusted loans | ||
Profit or loss from changes in fair value of | ||
investment properties using the fair value | ||
model for subsequent measurement | ||
One-off adjustment to profit or loss for | ||
the current period in accordance with | ||
laws and regulations on taxation and | ||
accounting | ||
Fees income from custodian business | ||
Other non-operating incomes and expenses | ||
other than the above items | -3,763,024.97 | |
Other profit or loss items falling within the | ||
meaning of non-recurring profit or loss | ||
Impact of non-controlling interests | ||
(after tax) | ||
Effect of income tax | -958,345.90 | |
Total | 13,922,444.09 | |
- 5 -
2.2 Total number of Shareholders and shareholding of top 10 Shareholders and top 10 holders of tradable shares (or Shareholders holding Shares not subject to trading restrictions) as at the end of the Reporting Period
Unit: share | |||||||
Total number of Shareholders | 21,198 | ||||||
Shareholding of top 10 Shareholders | |||||||
Number of | |||||||
Shares held as | Number of | ||||||
at the end of | Shares subject | Pledged or frozen Shares | |||||
the Reporting | Percentage | to trading | Nature of | ||||
Full name of shareholder | |||||||
Period | (%) | restrictions | Status | Number | Shareholder | ||
Feng Yuxia | 64,073,468 | 23.66% | 0 | Nil | 0 | Domestic natural | |
person | |||||||
HKSCC NOMINEES | 43,359,499 | 16.01% | 0 | Nil | 0 | Overseas legal | |
LIMITED | entity | ||||||
Zhou Zhiwen | 34,568,986 | 12.76% | 0 | Nil | 0 | Domestic natural | |
person | |||||||
Gu Xiaolei | 16,078,455 | 5.94% | 0 | Pledged | 5,600,000 | Domestic natural | |
person | |||||||
Hong Kong Securities | 12,802,584 | 4.73% | 0 | Nil | 0 | Overseas legal | |
Clearing Company Limited | entity | ||||||
Gu Meifang | 11,008,078 | 4.06% | 0 | Pledged | 8,720,000 | Domestic natural | |
person | |||||||
Zuo Conglin | 9,900,032 | 3.66% | 31,976 | Pledged | 2,305,000 | Domestic natural | |
person | |||||||
National Social Security | 5,768,878 | 2.13% | 0 | Nil | 0 | Others | |
Fund (Combination 406) | |||||||
Industrial and Commercial | 2,643,360 | 0.98% | 0 | Nil | 0 | Others | |
Bank of China Limited - | |||||||
China-Europe Medical and | |||||||
Health Hybrid Securities | |||||||
Investment Fund | |||||||
China Construction Bank | 2,300,000 | 0.85% | 0 | Nil | 0 | Others | |
Corporation Fund | |||||||
(中國建設銀行股份有限公 | |||||||
司-工銀瑞信前沿醫療股 | |||||||
票型證券投資基金) |
- 6 -
Shareholdings of top 10 holders of Shares not subject to trading restrictions
Number of | |||
Shares not | Class and number of shares | ||
subject to | |||
Name of shareholder | trading | ||
restrictions | Class | Number | |
Feng Yuxia | 64,073,468 | RMB-denominated | 64,073,468 |
ordinary shares | |||
HKSCC NOMINEES LIMITED | 43,359,499 | Overseas-listed | 43,359,499 |
foreign shares | |||
Zhou Zhiwen | 34,568,986 | RMB-denominated | 34,568,986 |
ordinary shares | |||
Gu Xiaolei | 16,078,455 | RMB-denominated | 16,078,455 |
ordinary shares | |||
Hong Kong Securities Clearing | 12,802,584 | RMB-denominated | 12,802,584 |
Company Limited | ordinary shares | ||
Gu Meifang | 11,008,078 | RMB-denominated | 11,008,078 |
ordinary shares | |||
Zuo Conglin | 9,868,056 | RMB-denominated | 9,868,056 |
ordinary shares | |||
National Social Security Fund | 5,768,878 | RMB-denominated | 5,768,878 |
(Combination 406) | ordinary shares | ||
Industrial and Commercial Bank of | 2,643,360 | RMB-denominated | 2,643,360 |
China Limited - China-Europe | ordinary shares | ||
Medical and Health Hybrid | |||
Securities Investment Fund | |||
China Construction Bank | 2,300,000 | RMB-denominated | 2,300,000 |
Corporation Fund (中國建設銀行 | ordinary shares | ||
股份有限公司-工銀瑞信前沿醫 | |||
療股票型證券投資基金) | |||
Description of connected | 1. Feng Yuxia and Zhou Zhiwen are in a spousal | ||
relationships or concerted actions | relationship; 2. Gu Meifang and Gu Xiaolei are aunt and | ||
of the above Shareholders | nephew. Except from this, the Company is not aware of | ||
any related party relationship among the shareholders | |||
mentioned above, and not aware of whether they are | |||
parties acting in concert. | |||
Description of preference | Nil | ||
shareholders with voting rights | |||
restored and their shareholdings | |||
Note: HKSCC NOMINEES LIMITED holds shares on behalf of multiple customers.
- 7 -
2.3 Total number of preference Shareholders and shareholdings of top 10 preference Shareholders and top 10 preference Shareholders not subject to trading restrictions as at the end of the Reporting Period
□ Applicable ✓ Not applicable
- Significant events
3.1 Significant changes in major financial statement items and financial indicators of the Company and the reasons thereof
✓ Applicable □ Not applicable
3.1.1 Reasons of significant changes in the items in the consolidated balance sheet during the Reporting Period
March 31, | December 31, | |||
Item | 2021 | 2020 | Change | Reasons |
Cash at bank and | 5,657,723,895.31 | 308,689,959.55 | 1,732.82% | Mainly due to the |
on hand | receipt of raised | |||
proceeds | ||||
Bills receivable | 3,020,000.00 | 2,175,000.00 | 38.85% | Mainly due to the |
increase in bills | ||||
received | ||||
Other receivables | 4,764,113.07 | 8,765,341.77 | -45.65% | Mainly due to the |
transfer of deposits | ||||
of land use rights to | ||||
payments | ||||
Right-of-use | 65,945,902.14 | Not | Mainly due to the | |
assets | applicable | adoption of new | ||
leasing standard | ||||
during the current | ||||
period | ||||
Deferred tax | 52,961,740.27 | 35,261,614.74 | 50.20% | Mainly due to the |
assets | increase in deductible | |||
temporary differences | ||||
in relation to share- | ||||
based payments due to | ||||
the increase in share | ||||
price | ||||
Other non-current | 58,011,580.39 | 36,232,987.14 | 60.11% | Mainly due to the |
assets | prepayment of land use | |||
right payments | ||||
Account payables | 80,814,491.38 | 60,285,553.10 | 34.05% | Mainly due to the |
increase in purchase | ||||
during the current | ||||
period | ||||
- 8 -
March 31, | December 31, | |||
Item | 2021 | 2020 | Change | Reasons |
Receipts in | 1,570,000.00 | -100.00% | Mainly due to the | |
advance | transfer of advance | |||
receipts from | ||||
customers to projects | ||||
during the current | ||||
period | ||||
Tax payables | 10,849,554.31 | 25,600,650.35 | -57.62% | Mainly due to the |
payment of 2020 | ||||
Enterprise Income | ||||
Tax during the current | ||||
period | ||||
Non-current | 17,772,483.59 | 3,080,988.42 | 476.84% | Mainly due to the |
liabilities due | adoption of new | |||
within one year | leasing standard | |||
during the current | ||||
period | ||||
Long-term | 9,690,467.43 | 21,375,166.75 | -54.66% | Mainly due to the |
borrowings | waiver of PPP loan | |||
of Biomere, our | ||||
subsidiary | ||||
Lease liabilities | 49,815,365.10 | Not | Mainly due to the | |
applicable | adoption of new | |||
leasing standard | ||||
during the current | ||||
period | ||||
Capital reserves | 5,518,563,086.27 | 249,804,268.45 | 2,109.15% | Mainly due to the |
listing on the Hong | ||||
Kong Stock Exchange | ||||
during the current | ||||
period | ||||
Other | -1,490,556.44 | 29,063,134.69 | -105.13% | Mainly due to the |
comprehensive | increase in investment | |||
income | costs of other equity | |||
instruments | ||||
Non-controlling | -992,185.95 | -734,936.01 | Not | Mainly due to the loss |
interests | applicable | of holding subsidiaries | ||
- 9 -
3.1.2 Reasons of significant changes in the items in the statement of profit or loss during the Reporting Period
January to | January to | |||
Item | March, 2021 | March, 2020 | Change | Reason |
Revenue | 200,992,535.41 | 154,713,623.00 | 29.91% | Mainly due to the |
increase in business | ||||
volume during the | ||||
current period | ||||
Costs | 97,328,314.02 | 78,798,635.04 | 23.52% | Mainly due to the |
increase in business | ||||
volume during the | ||||
current period | ||||
Taxes and | 1,605,433.14 | 1,116,338.97 | 43.81% | Mainly due to the |
surcharges | increase in business | |||
volume during the | ||||
current period | ||||
Administration | 67,109,647.64 | 46,013,786.64 | 45.85% | Mainly due to the |
expenses | increase in labor | |||
costs and office | ||||
expense | ||||
Finance expenses | -67,795,020.99 | -456,002.54 | Not | Mainly due to the |
applicable | exchange gain arising | |||
from the raised | ||||
proceeds received | ||||
during the current | ||||
period | ||||
Other income | 17,483,886.23 | 4,572,839.64 | 282.34% | Mainly due to the |
waiver of PPP loan | ||||
obtained by Biomere, | ||||
our subsidiary | ||||
Gains from | 902,485.17 | -461,656.92 | Not | Mainly due to the |
changes in fair | applicable | fair value change in | ||
value | biological assets | |||
Credit | -924,776.37 | 2,284,159.12 | -140.49% | Mainly due to the |
impairment | provision for credit | |||
losses | impairment losses | |||
during the current | ||||
period | ||||
Impairment | -1,112,952.02 | 162,923.96 | -783.11% | Mainly due to the |
losses | increase in provision | |||
for decline in prices | ||||
of inventories during | ||||
the current period | ||||
- 10 -
January to | January to | |||
Item | March, 2021 | March, 2020 | Change | Reason |
Non-operating | 6,705.00 | 240.00 | 2,693.75% | Mainly due to the |
income | increase in scrap | |||
sales during the | ||||
current period | ||||
Non-operating | 3,774,197.84 | 436,406.69 | 764.84% | Mainly due to the |
expense | increase in donation | |||
expense during the | ||||
current period | ||||
Profit before | 104,035,964.94 | 21,934,613.06 | 374.30% | Mainly due to the |
income tax | increase in business | |||
volume during the | ||||
current period | ||||
Income tax | 10,935,949.62 | 3,146,089.08 | 247.60% | Mainly due to the |
expense | increase in business | |||
volume during the | ||||
current period | ||||
Net cash flow | -66,686,497.84 | -29,737,009.85 | Not | Mainly due to the |
generated | applicable | net increase in | ||
from investing | investments of wealth | |||
activities | management products | |||
and the increase in | ||||
purchase of long- | ||||
term assets | ||||
Net cash | 5,312,443,354.88 | 1,602,158.28 | 331,480.43% | Mainly due to the |
generated | receipt of raised | |||
from financing | proceeds during the | |||
activities | current period | |||
- Analysis and explanations of the progress, impact and solution of significant events
- Applicable ✓ Not applicable
- Undertakings not performed during the Reporting Period
- Applicable ✓ Not applicable
- 11 -
3.4 Caution and explanation as to the anticipated loss of accumulated net profit from the beginning of the year to the end of the next reporting period or significant changes over the same period of last year
□ Applicable ✓ Not applicable
Company name | Joinn Laboratories (China) Co., Ltd. |
Legal Representative | Feng Yuxia |
Date | April 29, 2021 |
IV. Appendix
4.1 Financial statement
Consolidated Balance Sheet
As at March 31, 2021
Prepared by: Joinn Laboratories (China) Co., Ltd.
Unit: RMB | Currency: RMB Type of audit: Unaudited | ||
As at | As at | ||
Item | March 31, 2021 | December 31, 2020 | |
Current assets: | |||
Cash at bank and on hand | 5,657,723,895.31 | 308,689,959.55 | |
Balances with clearing companies | |||
Placements with banks and other | |||
financial institutions | |||
Financial assets held for trading | 223,543,843.83 | 238,902,999.99 | |
Derivative financial assets | |||
Bills receivables | 3,020,000.00 | 2,175,000.00 | |
Account receivables | 75,154,346.01 | 88,866,136.10 | |
Receivables financing | |||
Prepayments | 42,581,612.38 | 49,509,582.85 | |
Premium receivables | |||
Reinsurance account receivables | |||
Deposit receivables from reinsurance | |||
contracts | |||
Other receivables | 4,764,113.07 | 8,765,341.77 | |
Including: Interest receivables | |||
Dividend receivables | |||
Financial assets purchased under | |||
agreements to resell | |||
Inventories | 519,993,150.90 | 406,214,711.26 | |
- 12 -
As at | As at | |
Item | March 31, 2021 | December 31, 2020 |
Contract assets | 61,693,088.71 | 66,812,242.99 |
Assets held-for-sale | ||
Non-current assets due within one | ||
year | ||
Other current assets | 15,654,839.78 | 12,974,960.25 |
Total current assets | 6,604,128,889.99 | 1,182,910,934.76 |
Non-current assets: | ||
Loans and advances to customers | ||
Debt investment | ||
Other debt investment | ||
Long-term receivables | ||
Long-term equity investments | ||
Investments in other equity instruments | 64,444,809.52 | 64,444,809.52 |
Other non-current financial assets | ||
Investment properties | ||
Fixed assets | 447,616,196.82 | 445,555,655.12 |
Construction in progress | 52,393,262.38 | 48,633,480.15 |
Biological assets for breeding | 18,130,166.72 | 19,433,780.68 |
Oil and gas assets | ||
Right-of-use assets | 65,945,902.14 | |
Intangible assets | 121,090,988.86 | 123,631,240.12 |
Development expenses | ||
Goodwill | 126,186,809.43 | 125,295,803.39 |
Long-term deferred expenditures | 23,077,775.41 | 26,421,330.44 |
Deferred tax assets | 52,961,740.27 | 35,261,614.74 |
Other non-current assets | 58,011,580.39 | 36,232,987.14 |
Total non-current assets | 1,029,859,231.94 | 924,910,701.30 |
Total assets | 7,633,988,121.93 | 2,107,821,636.06 |
Current liabilities: | ||
Short-term borrowings | ||
Borrowings from central bank | ||
Placement from banks and other | ||
financial institutions | ||
Financial liabilities held for treading | ||
Derivative financial liabilities | ||
Bills payables | ||
- 13 -
As at | As at | |
Item | March 31, 2021 | December 31, 2020 |
Account payables | 80,814,491.38 | 60,285,553.10 |
Receipts in advance | 1,570,000.00 | |
Contract liabilities | 689,009,387.93 | 583,537,351.54 |
Financial assets sold under | ||
agreements to repurchase | ||
Deposits from customers and banks | ||
Customer deposits for securities | ||
trading | ||
Customer deposits for securities | ||
underwriting | ||
Employee benefit payables | 42,398,423.15 | 49,700,312.39 |
Tax payables | 10,849,554.31 | 25,600,650.35 |
Other payables | 30,489,542.06 | 32,997,002.18 |
Including: Interest payables | ||
Dividend payables | ||
Handling charges and commission | ||
payable | ||
Reinsurance account payables | ||
Liabilities held-for-sale | ||
Non-current liabilities due within one | ||
year | 17,772,483.59 | 3,080,988.42 |
Other current liabilities | 3,786,397.71 | 3,270,304.53 |
Total current liabilities | 875,120,280.13 | 760,042,162.51 |
Non-current liabilities: | ||
Deposits for insurance contracts | ||
Long-term borrowings | 9,690,467.43 | 21,375,166.75 |
Debenture payables | ||
Including: Preference shares | ||
Perpetual bonds | ||
Lease liabilities | 49,815,365.10 | |
Long-term payables | ||
Long-term payroll payables | ||
Projected liabilities | ||
Deferred income | 64,318,990.21 | 67,040,785.16 |
Deferred tax liabilities | 38,721,782.39 | 35,199,365.36 |
Other non-current liabilities | ||
Total non-current liabilities | 162,546,605.13 | 123,615,317.27 |
- 14 -
As at | As at | ||||
Item | March 31, 2021 | December 31, 2020 | |||
Total liabilities | 1,037,666,885.26 | 883,657,479.78 | |||
Owners' equity (or shareholders' | |||||
equity): | |||||
Paid up capital (or share capital) | 270,820,329.00 | 227,454,729.00 | |||
Other equity instruments | |||||
Including: Preference shares | |||||
Perpetual bonds | |||||
Capital reserves | 5,518,563,086.27 | 249,804,268.45 | |||
Less: Treasury shares | 9,915,527.00 | 9,915,527.00 | |||
Other comprehensive income | -1,490,556.44 | 29,063,134.69 | |||
Special reserve | |||||
Surplus reserve | 59,290,828.07 | 59,290,828.07 | |||
General risks reserve | |||||
Retained earnings | 760,045,262.72 | 669,201,659.08 | |||
Total owners' equity (or shareholders' | |||||
equity) attributable to the parent | |||||
company | 6,597,313,422.62 | 1,224,899,092.29 | |||
Non-controlling interests | -992,185.95 | -734,936.01 | |||
Total owners' equity | |||||
(or shareholders' equity) | 6,596,321,236.67 | 1,224,164,156.28 | |||
Total liabilities and owners' | |||||
equity (or shareholders' | |||||
equity) | 7,633,988,121.93 | 2,107,821,636.06 | |||
Director of | |||||
Legal Representative: | Chief Financial Officer: | the Accounting Department: | |||
Feng Yuxia | Yu Aishui | Yu Aishui |
- 15 -
Balance Sheet of the Parent Company
As at March 31, 2021
Prepared by: Joinn Laboratories (China) Co., Ltd.
Unit: RMB | Currency: RMB | Audit status: Unaudited | ||
As at | As at | |||
Item | March 31, 2021 | December 31, 2020 | ||
Current assets: | ||||
Cash at bank and on hand | 5,415,296,923.30 | 49,939,882.78 | ||
Financial assets held for trading | 162,644,747.94 | 208,003,904.10 | ||
Derivative financial assets | ||||
Bills receivables | ||||
Account receivables | 21,978,844.75 | 7,980,312.02 | ||
Receivables financing | ||||
Prepayments | 30,538,027.44 | 27,191,935.98 | ||
Other receivables | 71,453,390.92 | 55,977,804.58 | ||
Including: Interest receivables | ||||
Dividend receivables | ||||
Inventories | 113,374,807.42 | 103,417,687.78 | ||
Contract assets | 30,866,884.31 | 34,223,306.49 | ||
Assets held-for-sale | ||||
Non-current assets due within one | ||||
year | ||||
Other current assets | 4,257,324.19 | 3,927,708.06 | ||
Total current assets | 5,850,410,950.27 | 490,662,541.79 | ||
Non-current assets: | ||||
Debt investment | ||||
Other debt investment | ||||
Long-term receivables | ||||
Long-term equity investments | 576,140,484.02 | 549,277,848.74 | ||
Investments in other equity | ||||
instruments | 64,444,809.52 | 64,444,809.52 | ||
Other non-current financial assets | ||||
Investment properties | ||||
Fixed assets | 110,110,052.13 | 120,373,701.14 | ||
Construction in progress | 1,973,617.77 | 2,137,481.93 | ||
Biological assets for breeding | ||||
Oil and gas assets | ||||
Right-of-use assets | 2,479,367.08 | |||
- 16 -
As at | As at | |
Item | March 31, 2021 | December 31, 2020 |
Intangible assets | 16,636,350.58 | 17,856,922.01 |
Development expenses | ||
Goodwill | ||
Long-term deferred expenditures | 3,665,173.50 | 3,672,458.65 |
Deferred tax assets | 18,865,461.06 | 10,414,065.73 |
Other non-current assets | 3,348,458.76 | 3,923,902.76 |
Total non-current assets | 797,663,774.42 | 772,101,190.48 |
Total assets | 6,648,074,724.69 | 1,262,763,732.27 |
Current liabilities: | ||
Short-term borrowings | ||
Financial liabilities held for trading | ||
Derivative financial liabilities | ||
Bills payables | ||
Account payables | 26,458,752.80 | 30,898,749.24 |
Receipts in advance | ||
Contract liabilities | 224,890,816.77 | 194,127,498.08 |
Employee benefit payables | 15,500,952.88 | 16,783,931.66 |
Tax payables | 2,420,850.42 | 1,201,325.41 |
Other payables | 37,938,199.24 | 16,168,322.16 |
Including: Interests payable | ||
Dividends payable | ||
Liabilities held-for-sale | ||
Non-current liabilities due within one | ||
year | 1,391,926.98 | |
Other current liabilities | 1,789,923.72 | 1,452,133.47 |
Total current liabilities | 310,391,422.81 | 260,631,960.02 |
Non-current liabilities: | ||
Long-term borrowings | ||
Debenture payables | ||
Including: Preference shares | ||
Perpetual bonds | ||
Lease liabilities | 1,452,894.68 | |
Long-term payables | ||
Long-term payroll payables | ||
Projected liabilities | ||
Deferred income | 13,771,318.06 | 14,107,308.34 |
- 17 -
As at | As at | ||||
Item | March 31, 2021 | December 31, 2020 | |||
Deferred tax liabilities | 17,974,359.95 | 13,885,085.02 | |||
Other non-current liabilities | |||||
Total non-current liabilities | 33,198,572.69 | 27,992,393.36 | |||
Total liabilities | 343,589,995.50 | 288,624,353.38 | |||
Owners' equity (or shareholders' | |||||
equity): | |||||
Paid up capital (or share capital) | 270,820,329.00 | 227,454,729.00 | |||
Other equity instruments | |||||
Including: Preference shares | |||||
Perpetual bonds | |||||
Capital reserves | 5,504,187,642.69 | 240,609,043.62 | |||
Less: Treasury shares | 9,915,527.00 | 9,915,527.00 | |||
Other comprehensive income | 12,278,088.09 | 44,578,088.09 | |||
Special reserve | |||||
Surplus reserve | 59,290,828.07 | 59,290,828.07 | |||
Retained earnings | 467,823,368.34 | 412,122,217.11 | |||
Total owners' equity (or | |||||
shareholders' equity) | 6,304,484,729.19 | 974,139,378.89 | |||
Total liabilities and owners' | |||||
equity (or shareholders' | |||||
equity) | 6,648,074,724.69 | 1,262,763,732.27 | |||
Director of | |||||
Legal Representative: | Chief Financial Officer: | the Accounting Department: | |||
Feng Yuxia | Yu Aishui | Yu Aishui |
- 18 -
Consolidated Income Statement
January to March 2021
Prepared by: Joinn Laboratories (China) Co., Ltd.
Unit: RMB | Currency: RMB | Audit status: Unaudited | ||
First | First | |||
Item | quarter of | quarter of | ||
2021 | 2020 | |||
I. Total revenue | 200,992,535.41 | 154,713,623.00 | ||
Including: Revenue | 200,992,535.41 | 154,713,623.00 | ||
Interest income | ||||
Premiums earned | ||||
Handling charges and | ||||
commission income | ||||
II. Total cost | 111,324,851.53 | 140,348,068.02 | ||
Including: Cost | 97,328,314.02 | 78,798,635.04 | ||
Interest expenses | ||||
Handling charges and | ||||
commission expenses | ||||
Payments on surrender | ||||
Net claim expenses | ||||
Net provision for | ||||
insurance contract | ||||
reserves | ||||
Policyholder dividend | ||||
expenses | ||||
Reinsurance costs | ||||
Taxes and surcharges | 1,605,433.14 | 1,116,338.97 | ||
Selling and marketing | ||||
expenses | 3,197,669.49 | 3,114,756.43 | ||
Administration expenses | 67,109,647.64 | 46,013,786.64 | ||
Research and development | ||||
expenses | 9,878,808.23 | 11,760,553.48 | ||
Finance expenses | -67,795,020.99 | -456,002.54 | ||
Including: Interest expense | 791,416.57 | 334,689.14 | ||
Interest income | 432,029.22 | 420,814.61 | ||
- 19 -
First | First | |
Item | quarter of | quarter of |
2021 | 2020 | |
Add: Other income | 17,483,886.23 | 4,572,839.64 |
Investment gains | ||
("-" indicating loss) | 1,787,131.49 | 1,449,051.36 |
Including: Gains from | ||
investment in | ||
associates and | ||
joint ventures | ||
Derecognition | ||
of income from | ||
financial assets | ||
measured at | ||
amortised cost | ||
Exchange gains | ||
("-" indicating loss) | ||
Gains from net | ||
exposure to | ||
hedging ("-" indicating loss) | ||
Gains from changes | ||
in fair value | ||
("-" indicating loss) | 902,485.17 | -461,656.92 |
Credit impairment | ||
losses ("-" indicating loss) | -924,776.37 | 2,284,159.12 |
Assets impairment | ||
losses ("-" indicating loss) | -1,112,952.02 | 162,923.96 |
Gains from disposal | ||
of assets ("-" indicating loss) | -0.60 | -2,092.39 |
III. Operating profit ("-" indicating | ||
loss) | 107,803,457.78 | 22,370,779.75 |
Add: Non-operating income | 6,705.00 | 240.00 |
Less: Non-operating expenses | 3,774,197.84 | 436,406.69 |
- 20 -
First | First | |||
Item | quarter of | quarter of | ||
2021 | 2020 | |||
IV. Profits before income tax ("-" | ||||
indicating total losses) | 104,035,964.94 | 21,934,613.06 | ||
Less: Income tax expenses | 10,935,949.62 | 3,146,089.08 | ||
V. Net profits ("-" indicating net loss) | 93,100,015.32 | 18,788,523.98 | ||
(I) Classified by the continuity of operation | ||||
1. | Net profit from continuing | |||
operations ("-" indicating net | ||||
loss) | 93,100,015.32 | 18,788,523.98 | ||
2. | Net profit from discontinued | |||
operations ("-" indicating net | ||||
loss) | ||||
(II) Classified by the ownership | ||||
1. | Net profit attributable to equity | |||
shareholders of the company ("-" | ||||
indicating net loss) | 93,357,265.26 | 19,127,779.80 | ||
2. | Profit and loss of non-controlling | |||
interests ("-" indicating net loss) | -257,249.94 | -339,255.82 | ||
VI. Other comprehensive income, net | ||||
of tax | -30,711,088.88 | 3,841,583.45 | ||
(I) Other comprehensive income | ||||
attributable to owners of the | ||||
parent company, net of tax | -30,711,088.88 | 3,841,583.45 | ||
1. | Other comprehensive income that | |||
will not be reclassified to profit or | ||||
loss | -32,300,000.00 | |||
(1) | Changes in re-measurement of | |||
defined benefit plans | ||||
(2) | Other comprehensive income that | |||
will not be transferred to profit or | ||||
loss accounted for using equity | ||||
method | ||||
(3) | Changes in fair value of | |||
investments in other equity | ||||
instruments | -32,300,000.00 | |||
(4) | Changes in fair value of the | |||
company's own credit risk | ||||
- 21 -
First | First | ||
Item | quarter of | quarter of | |
2021 | 2020 | ||
2. Other comprehensive income that | |||
will be reclassified to profit or loss | 1,588,911.12 | 3,841,583.45 | |
(1)Other comprehensive income that | |||
will be transferred to profit or loss | |||
accounted for using equity method | |||
(2) | Changes in fair value of other debt | ||
investments | |||
(3) | Financial assets reclassified to | ||
other comprehensive income | |||
(4) | Credit impairment allowance of | ||
other debt investments | |||
(5) | Cash flow hedging reserve | ||
(6) | Exchange difference on translation | ||
of foreign financial statements | 1,588,911.12 | 3,841,583.45 | |
(7) | Others | ||
(II) Other comprehensive income | |||
attributable to minority shareholders, | |||
net of tax | |||
VII.Total comprehensive income | 62,388,926.44 | 22,630,107.43 | |
(1) | Total comprehensive income | ||
attributable to equity shareholders | |||
of the parent company | 62,646,176.38 | 22,969,363.25 | |
(2) | Total comprehensive income | ||
attributable to non-controlling | |||
interests | -257,249.94 | -339,255.82 | |
VIII.Earnings per share: | |||
(I) Basic earnings per share (RMB | |||
per share) | 0.39 | 0.09 | |
(II) Diluted earnings per share (RMB | |||
per share) | 0.38 | 0.09 | |
For the business combination involving enterprises under common control during the Reporting Period, realised net profit of the merged parties before the merger was RMB0 (corresponding period of the previous year: RMB0).
Director of | ||
Legal Representative: | Chief Financial Officer: | the Accounting Department: |
Feng Yuxia | Yu Aishui | Yu Aishui |
- 22 -
Income Statement of the Parent Company
January to March 2021
Prepared by: Joinn Laboratories (China) Co., Ltd.
Unit: RMB | Currency: RMB Type of audit: Unaudited | ||
First Quarter of | First Quarter of | ||
Item | 2021 | 2020 | |
I. Revenue | 50,746,980.14 | 39,507,445.16 | |
Less: Cost | 29,339,699.35 | 21,102,445.67 | |
Taxes and surcharges | 567,528.04 | 423,070.27 | |
Selling and marketing expenses | 1,790,700.15 | 1,414,210.51 | |
Administration expenses | 20,137,217.46 | 12,897,768.77 | |
Research and development | |||
expenses | 3,091,008.59 | 5,883,412.68 | |
Finance expenses | -67,971,575.70 | -45,241.27 | |
Including: Interest expense | 35,500.98 | 80,365.17 | |
Interest income | 136,088.15 | 123,547.90 | |
Add: Other income | 1,255,969.02 | 3,485,712.94 | |
Investment income | |||
("-" indicating losses) | -8,212,868.51 | 1,417,202.05 | |
Including: Gains from | |||
investments in associates and | |||
joint ventures | |||
Derecognition of income from | |||
financial assets measured at | |||
amortised cost | |||
Gains from net exposure to | |||
hedging ("-" indicating losses) | |||
Gains from changes in fair | |||
value ("-" indicating losses) | -359,156.16 | -484,261.75 | |
Credit impairment losses ("-" | |||
indicating losses) | -37,874.82 | -365,606.53 | |
Assets impairment losses ("-" | |||
indicating losses) | 9,777,104.64 | -606,003.45 | |
Gains from disposal of assets | |||
("-" indicating losses) | -0.60 | ||
- 23 -
First Quarter of | First Quarter of | |
Item | 2021 | 2020 |
II. Operating profit ("-" indicating | ||
losses) | 66,215,575.82 | 1,278,821.79 |
Add: Non-operating income | 1,905.00 | 240.00 |
Less: Non-operating expenses | 1,246,320.75 | 1,970.77 |
III. Profit before income tax | ||
("-" indicating total loss) | 64,971,160.07 | 1,277,091.02 |
Less: Income tax expenses | 8,910,336.98 | 342,635.93 |
IV. Net profits ("-" indicating net loss) | 56,060,823.09 | 934,455.09 |
(I) Net profit from continuing | ||
operations ("-" indicating net loss) | 56,060,823.09 | 934,455.09 |
(II)Net profit from discontinued | ||
operations ("-" indicating net loss) | ||
V. Other comprehensive income (net of | ||
tax) | -32,300,000.00 | |
(I) Other comprehensive income that | ||
will not be reclassified to profit or | ||
loss | -32,300,000.00 | |
1. Changes in re-measurement of | ||
defined benefit plans | ||
2. Other comprehensive income | ||
that will not be transferred to | ||
profit or loss accounted for using | ||
equity method | ||
3. Changes in fair value of | ||
investments in other equity | ||
instruments | -32,300,000.00 | |
4. Changes in fair value of the | ||
company's own credit risk | ||
- 24 -
First Quarter of | First Quarter of | ||||
Item | 2021 | 2020 | |||
(II) Other comprehensive income that | |||||
will be reclassified to profit or | |||||
loss | |||||
1. | Other comprehensive income | ||||
that will be transferred to profit | |||||
or loss accounted for using | |||||
equity method | |||||
2. | Changes in fair value of other | ||||
debt investments | |||||
3. | Financial assets reclassified to | ||||
other comprehensive income | |||||
4. | Credit impairment allowance of | ||||
other debt investments | |||||
5. | Cash flow hedging reserve | ||||
6. | Exchange difference on | ||||
translation of foreign financial | |||||
statements | |||||
7. | Others | ||||
VI. Total comprehensive income | 23,760,823.09 | 934,455.09 | |||
VII. Earnings per share: | |||||
(I) Basic earnings per share (RMB | |||||
per share) | |||||
(II) Diluted earnings per share (RMB | |||||
per share) | |||||
Director of | |||||
Legal Representative: | Chief Financial Officer: the Accounting Department: | ||||
Feng Yuxia | Yu Aishui | Yu Aishui |
- 25 -
Consolidated Cash Flow Statement
January to March 2021
Prepared by: Joinn Laboratories (China) Co., Ltd.
Unit: RMB | Currency: RMB Type of audit: Unaudited | ||
First quarter of | First quarter of | ||
Item | 2021 | 2020 | |
I. Cash flows from operating | |||
activities: | |||
Cash received from the sale of goods | |||
and rendering of services | 334,525,902.11 | 232,670,305.50 | |
Net increase in deposits from | |||
customers and placements from | |||
bank and other financial institutions | |||
Net increase in borrowings from | |||
central bank | |||
Net increase in borrowings from | |||
other financial institutions | |||
Cash received from premiums of | |||
original insurance contracts | |||
Net cash received from reinsurance | |||
operations | |||
Net increase in policyholders' | |||
deposits and investments | |||
Cash received from interest, handling | |||
charges and commission | |||
Net increase in loans from banks and | |||
other financial institutions | |||
Net increase in capital for repurchase | |||
Net cash received from securities | |||
trading agency services | |||
Refund of taxes and surcharges | |||
Cash received from other operating | |||
activities | 3,462,521.84 | 2,732,314.55 | |
Sub-total of cash inflow from | |||
operating activities | 337,988,423.95 | 235,402,620.05 | |
Cash paid for goods purchased and | |||
service rendered | 145,523,146.29 | 75,601,523.86 | |
Net increase in loans and advances to | |||
customers | |||
Net increase in placements with | |||
central bank and other financial | |||
institutions | |||
- 26 -
First quarter of | First quarter of | |
Item | 2021 | 2020 |
Cash paid for claims on original | ||
insurance contracts | ||
Net increase in loans to banks and | ||
other financial institutions | ||
Cash paid for interest, handling | ||
charges and commission | ||
Cash paid for policyholders' dividend | ||
Cash paid to and on behalf employees | 99,499,941.50 | 87,788,130.10 |
Taxes paid | 27,767,984.36 | 17,360,247.52 |
Cash paid for other operating | ||
activities | 30,715,269.04 | 20,337,535.13 |
Subtotal of cash outflow from | ||
operating activities | 303,506,341.19 | 201,087,436.61 |
Net cash flow from operating | ||
activities | 34,482,082.76 | 34,315,183.44 |
II. Cash flow from investing activities: | ||
Cash received from disposal of | ||
investments | 95,000,000.00 | 200,633,640.41 |
Cash received from returns on | ||
investment | 1,787,131.49 | 442,671.22 |
Net cash received from disposal of | ||
fixed assets, intangible assets and | ||
other long-term assets | 13,180.00 | 1,000.00 |
Net cash received from disposal of | ||
subsidiaries and other business | ||
entities | ||
Cash received from other investing | ||
activities | ||
Subtotal of cash inflow from | ||
investing activities | 96,800,311.49 | 201,077,311.63 |
Cash paid to acquire fixed assets, | ||
intangible assets and other long- | ||
term assets | 45,486,809.33 | 27,319,871.48 |
Cash paid to acquire investments | 118,000,000.00 | 203,494,450.00 |
Net increase in pledged loans | ||
Net cash paid for acquisition of | ||
subsidiaries and other business | ||
entities | ||
Cash paid for other investing | ||
activities | ||
- 27 -
First quarter of | First quarter of | |||
Item | 2021 | 2020 | ||
Subtotal of cash outflow from | ||||
investing activities | 163,486,809.33 | 230,814,321.48 | ||
Net cash flow from investing | ||||
activities | -66,686,497.84 | -29,737,009.85 | ||
III.Cash flow from financing activities: | ||||
Cash received from capital | ||||
contributions | 5,318,194,000.94 | |||
Including: Cash received from | ||||
capital contribution by | ||||
minority shareholders of | ||||
subsidiaries | ||||
Cash received from borrowings | 24,073,120.00 | |||
Cash received relating to other | ||||
financing activities | ||||
Sub-total of cash inflow from | ||||
financing activities | 5,318,194,000.94 | 24,073,120.00 | ||
Cash repayments of borrowings | 759,417.16 | 22,136,272.58 | ||
Cash payments for distribution | ||||
of dividends, profits or interest | ||||
expenses | 116,527.70 | 334,689.14 | ||
Including: Dividends and profits paid | ||||
by subsidiaries to non- | ||||
controlling interests | ||||
Cash payments relating to other | ||||
financing activities | 4,874,701.20 | |||
Sub-total of cash outflow from | ||||
financing activities | 5,750,646.06 | 22,470,961.72 | ||
Net cash flow from financing | ||||
activities | 5,312,443,354.88 | 1,602,158.28 | ||
IV.Effect of foreign exchange | ||||
rate changes on cash and cash | ||||
equivalents | 68,794,995.96 | 1,650,078.20 | ||
V. Net increase in cash and cash | ||||
equivalents | 5,349,033,935.76 | 7,830,410.07 | ||
Add: Cash and cash equivalents at the | ||||
beginning of the period | 305,043,920.05 | 175,957,784.22 | ||
VI.Cash and cash equivalents at the | ||||
end of the period | 5,654,077,855.81 | 183,788,194.29 | ||
Director of | ||||
Legal Representative: | Chief Financial Officer: the Accounting Department: | |||
Feng Yuxia | Yu Aishui | Yu Aishui |
- 28 -
Cash Flow Statement of the Parent Company
January to March 2021
Prepared by: Joinn Laboratories (China) Co., Ltd.
Unit: RMB | Currency: RMB Type of audit: Unaudited | ||
First quarter of | First quarter of | ||
Item | 2021 | 2020 | |
I. Cash flow from operating activities: | |||
Cash received from sale of goods or | |||
rendering of services | 76,503,028.57 | 57,985,149.58 | |
Refund of taxes and surcharges | |||
Cash received relating to other | |||
operating activities | 50,807,677.80 | 10,390,350.91 | |
Sub-total of cash inflow from | |||
operating activities | 127,310,706.37 | 68,375,500.49 | |
Cash paid for purchasing goods and | |||
receiving services | 48,742,359.11 | 24,949,461.07 | |
Cash paid to and on behalf of | |||
employees | 28,762,505.41 | 31,000,317.07 | |
Payments of taxes and surcharges | 2,096,937.96 | 5,363,174.46 | |
Cash paid relating to other operating | |||
activities | 44,761,446.97 | 4,914,147.78 | |
Sub-total of cash outflow from | |||
operating activities | 124,363,249.45 | 66,227,100.38 | |
Net cash flow from operating | |||
activities | 2,947,456.92 | 2,148,400.11 | |
II. Cash flow from investing activities: | |||
Cash received from disposal of | |||
investments | 95,000,000.00 | 190,633,640.41 | |
Cash received from returns on | |||
investments | 1,787,131.49 | 410,821.91 | |
Net cash received from disposal of | |||
fixed assets, intangible assets and | |||
other long-term assets | 280.00 | ||
Net cash received from disposal of | |||
subsidiaries and other business | |||
entities | |||
Cash received relating to other | |||
investing activities | |||
Sub-total of cash inflow from | |||
investing activities | 96,787,411.49 | 191,044,462.32 | |
Cash paid to acquire fixed assets, | |||
intangible assets and other long- | |||
term assets | 3,756,772.00 | 6,450,277.70 | |
- 29 -
First quarter of | First quarter of | |||
Item | 2021 | 2020 | ||
Cash paid to acquire investments | 112,000,000.00 | 193,000,000.00 | ||
Net cash paid to acquire subsidiaries | ||||
and other business entities | ||||
Cash paid relating to other investing | ||||
activities | ||||
Sub-total of cash outflow from | ||||
investing activities | 115,756,772.00 | 199,450,277.70 | ||
Net cash flow from investing | ||||
activities | -18,969,360.51 | -8,405,815.38 | ||
III.Cash flow from financing activities: | ||||
Cash received from capital | ||||
contributions | 5,318,194,000.94 | |||
Cash received from borrowings | 18,482,000.00 | |||
Cash received relating to other | ||||
financing activities | ||||
Sub-total of cash inflow from | ||||
financing activities | 5,318,194,000.94 | 18,482,000.00 | ||
Cash repayments of borrowings | 18,482,000.00 | |||
Cash payments for distribution | ||||
of dividends, profits or interest | ||||
expenses | 80,365.17 | |||
Cash paid relating to other financing | ||||
activities | 4,874,701.20 | |||
Sub-total of cash outflow from | ||||
financing activities | 4,874,701.20 | 18,562,365.17 | ||
Net cash flow from financing | ||||
activities | 5,313,319,299.74 | -80,365.17 | ||
IV.Effect of foreign exchange | ||||
rate changes on cash and cash | ||||
equivalents | 68,059,644.37 | 49,037.91 | ||
V. Net increase in cash and cash | ||||
equivalents | 5,365,357,040.52 | -6,288,742.53 | ||
Add: Cash and cash equivalents at | ||||
the beginning of the period | 49,939,882.78 | 39,455,567.02 | ||
VI.Cash and cash equivalents at the | ||||
end of the period | 5,415,296,923.30 | 33,166,824.49 | ||
Director of | ||||
Legal Representative: | Chief Financial Officer: the Accounting Department: | |||
Feng Yuxia | Yu Aishui | Yu Aishui |
- 30 -
4.2 Adjustments on the financial statements at the beginning of the first year of adopting new leasing standards since 2021
- Applicable □ Not applicable
Consolidated Balance Sheet | |||||
Unit: RMB | Currency: RMB | ||||
As at | As at | ||||
Item | December 31, 2020 | January 1, 2021 | Adjustment | ||
Current assets: | |||||
Cash at bank and on hand | 308,689,959.55 | 308,689,959.55 | |||
Balances with clearing | |||||
companies | |||||
Placements with banks and | |||||
other financial institutions | |||||
Financial assets held for | 238,902,999.99 | 238,902,999.99 | |||
trading | |||||
Derivative financial assets | |||||
Bills receivables | 2,175,000.00 | 2,175,000.00 | |||
Account receivables | 88,866,136.10 | 88,866,136.10 | |||
Receivables financing | |||||
Prepayments | 49,509,582.85 | 49,509,582.85 | |||
Premium receivables | |||||
Reinsurance account | |||||
receivables | |||||
Deposit receivables from | |||||
reinsurance contracts | |||||
Other receivables | 8,765,341.77 | 8,765,341.77 | |||
Including: Interest | |||||
receivables | |||||
Dividend | |||||
receivables | |||||
Financial assets purchased | |||||
under agreements to resell | |||||
Inventories | 406,214,711.26 | 406,214,711.26 | |||
Contract assets | 66,812,242.99 | 66,812,242.99 | |||
Assets held-for-sale | |||||
Non-current assets due | |||||
within one year | |||||
- 31 -
As at | As at | ||
Item | December 31, 2020 | January 1, 2021 | Adjustment |
Other current assets | 12,974,960.25 | 12,750,717.63 | -224,242.62 |
Total current assets | 1,182,910,934.76 | 1,182,686,692.14 | -224,242.62 |
Non-current assets: | |||
Loans and advances to | |||
customers | |||
Debt investment | |||
Other debt investment | |||
Long-term receivables | |||
Long-term equity | |||
investments | |||
Investments in other equity | 64,444,809.52 | 64,444,809.52 | |
instruments | |||
Other non-current financial | |||
assets | |||
Investment properties | |||
Fixed assets | 445,555,655.12 | 445,555,655.12 | |
Construction in progress | 48,633,480.15 | 48,633,480.15 | |
Biological assets for | 19,433,780.68 | 19,433,780.68 | |
breeding | |||
Oil and gas assets | |||
Right-of-use assets | 69,143,724.01 | 69,143,724.01 | |
Intangible assets | 123,631,240.12 | 123,631,240.12 | |
Development expenses | |||
Goodwill | 125,295,803.39 | 125,295,803.39 | |
Long-term deferred | 26,421,330.44 | 22,581,205.46 | -3,840,124.98 |
expenditures | |||
Deferred tax assets | 35,261,614.74 | 35,261,614.74 | |
Other non-current assets | 36,232,987.14 | 36,232,987.14 | |
Total non-current assets | 924,910,701.30 | 990,214,300.33 | 65,303,599.03 |
Total assets | 2,107,821,636.06 | 2,172,900,992.47 | 65,079,356.41 |
Current liabilities: | |||
Short-term borrowings | |||
Borrowings from central | |||
bank | |||
Placement from banks and | |||
other financial institutions | |||
Financial liabilities held for | |||
trading | |||
- 32 -
As at | As at | |||
Item | December 31, 2020 | January 1, 2021 | Adjustment | |
Derivative financial | ||||
liabilities | ||||
Bills payables | ||||
Account payables | 60,285,553.10 | 60,285,553.10 | ||
Receipts in advance | 1,570,000.00 | 1,570,000.00 | ||
Contract liabilities | 583,537,351.54 | 583,537,351.54 | ||
Financial assets sold under | ||||
agreements to repurchase | ||||
Deposits from customers and | ||||
banks | ||||
Customer deposits for | ||||
securities trading | ||||
Customer deposits for | ||||
securities underwriting | ||||
Employee benefit payables | 49,700,312.39 | 49,700,312.39 | ||
Tax payables | 25,600,650.35 | 25,600,650.35 | ||
Other payables | 32,997,002.18 | 32,742,752.18 | -254,250.00 | |
Including: | Interest | |||
payables | ||||
Dividend | ||||
payables | ||||
Handling charges and | ||||
commission payable | ||||
Reinsurance account | ||||
payables | ||||
Liabilities held-for-sale | ||||
Non-current liabilities due | 3,080,988.42 | 17,600,778.09 | 14,519,789.67 | |
within one year | ||||
Other current liabilities | 3,270,304.53 | 3,270,304.53 | ||
Total current liabilities | 760,042,162.51 | 774,307,702.18 | 14,265,539.67 | |
Non-current liabilities: | ||||
Deposits for insurance | ||||
contracts | ||||
Long-term borrowings | 21,375,166.75 | 21,375,166.75 | ||
Debenture payables | ||||
Including: | Preference | |||
shares | ||||
Perpetual bonds | ||||
- 33 -
As at | As at | ||
Item | December 31, 2020 | January 1, 2021 | Adjustment |
Lease liabilities | 53,170,080.61 | 53,170,080.61 | |
Long-term payables | |||
Long-term payroll payable | |||
Projected liabilities | |||
Deferred income | 67,040,785.16 | 67,040,785.16 | |
Deferred tax liabilities | 35,199,365.36 | 35,199,365.36 | |
Other non-current liabilities | |||
Total non-current | 123,615,317.27 | 176,785,397.88 | 53,170,080.61 |
liabilities | |||
Total liabilities | 883,657,479.78 | 951,093,100.06 | 67,435,620.28 |
Owners' equity (or | |||
shareholders' equity): | |||
Paid up capital (or share | 227,454,729.00 | 227,454,729.00 | |
capital) | |||
Other equity instruments | |||
Including: Preference | |||
shares | |||
Perpetual bonds | |||
Capital reserves | 249,804,268.45 | 249,804,268.45 | |
Less: Treasury shares | 9,915,527.00 | 9,915,527.00 | |
Other comprehensive income | 29,063,134.69 | 29,220,532.44 | 157,397.75 |
Special reserve | |||
Surplus reserve | 59,290,828.07 | 59,290,828.07 | |
General risks reserve | |||
Retained earnings | 669,201,659.08 | 666,687,997.46 | -2,513,661.62 |
Total owners' equity (or | 1,224,899,092.29 | 1,222,542,828.42 | -2,356,263.87 |
shareholders' equity) | |||
attributable to the parent | |||
company | |||
Non-controlling interests | -734,936.01 | -734,936.01 | |
Total owners' equity (or | 1,224,164,156.28 | 1,221,807,892.41 | -2,356,263.87 |
shareholders' equity) | |||
Total liabilities and | 2,107,821,636.06 | 2,172,900,992.47 | 65,079,356.41 |
owners' equity (or | |||
shareholders' equity) | |||
- 34 -
Explanation of adjustment of each item:
- Applicable □ Not applicable
In December 2018, the Ministry of Finance of the People's Republic of China issued the Circular regarding Amendments on the PRC Accounting Standards for Business Enterprises No. 21 - Leases (Cai Kuai [2018] No. 35). Upon approval by the Board, the Company announced the adoption of above revised accounting standards in the Group commencing on January 1, 2021. Due to cumulative effect of the adoption, the Group adjusted the opening balance of retained earnings and the amounts of other related items in the financial statements at the beginning of the year (in which this standard was initially adopted). The data of comparable period shall not be adjusted.
Balance Sheet of the Parent Company
Unit: RMB | Currency: RMB | |||
Item | As at | As at | Adjustment | |
December 31, 2020 | January 1, 2021 | |||
Current assets: | ||||
Cash at bank and on hand | 49,939,882.78 | 49,939,882.78 | ||
Financial assets held for | 208,003,904.10 | 208,003,904.10 | ||
trading | ||||
Derivative financial assets | ||||
Bills receivables | ||||
Account receivables | 7,980,312.02 | 7,980,312.02 | ||
Receivables financing | ||||
Prepayments | 27,191,935.98 | 27,191,935.98 | ||
Other receivables | 55,977,804.58 | 55,977,804.58 | ||
Including: Interest | ||||
receivables | ||||
Dividend | ||||
receivables | ||||
Inventories | 103,417,687.78 | 103,417,687.78 | ||
Contract assets | 34,223,306.49 | 34,223,306.49 | ||
Assets held-for-sale | ||||
Non-current assets due within | ||||
one year | ||||
Other current assets | 3,927,708.06 | 3,927,708.06 | ||
Total current assets | 490,662,541.79 | 490,662,541.79 | ||
Non-current assets: | ||||
Debt investments | ||||
Other debt investments | ||||
Long-term receivables | ||||
- 35 -
Item | As at | As at | Adjustment |
December 31, 2020 | January 1, 2021 | ||
Long-term equity investments | 549,277,848.74 | 549,277,848.74 | |
Investments in other equity | 64,444,809.52 | 64,444,809.52 | |
instruments | |||
Other non-current financial | |||
assets | |||
Investment properties | |||
Fixed assets | 120,373,701.14 | 120,373,701.14 | |
Construction in progress | 2,137,481.93 | 2,137,481.93 | |
Biological assets for breeding | |||
Oil and gas assets | |||
Right-of-use assets | 2,776,891.12 | 2,776,891.12 | |
Intangible assets | 17,856,922.01 | 17,856,922.01 | |
Development expenses | |||
Goodwill | |||
Long-term deferred | 3,672,458.65 | 3,672,458.65 | |
expenditures | |||
Deferred tax assets | 10,414,065.73 | 10,414,065.73 | |
Other non-current assets | 3,923,902.76 | 3,923,902.76 | |
Total non-current assets | 772,101,190.48 | 774,878,081.60 | 2,776,891.12 |
Total assets | 1,262,763,732.27 | 1,265,540,623.39 | 2,776,891.12 |
Current liabilities: | |||
Short-term borrowings | |||
Financial liabilities held for | |||
trading | |||
Derivative financial liabilities | |||
Bills payables | |||
Account payables | 30,898,749.24 | 30,898,749.24 | |
Receipts in advance | |||
Contract liabilities | 194,127,498.08 | 194,127,498.08 | |
Employee benefit payables | 16,783,931.66 | 16,783,931.66 | |
Tax payables | 1,201,325.41 | 1,201,325.41 | |
Other payables | 16,168,322.16 | 16,168,322.16 | |
Including: Interest payables | |||
Dividend | |||
payables | |||
Liabilities held-for-sale | |||
- 36 -
Item | As at | As at | Adjustment |
December 31, 2020 | January 1, 2021 | ||
Non-current liabilities due | 1,362,778.04 | 1,362,778.04 | |
within one year | |||
Other current liabilities | 1,452,133.47 | 1,452,133.47 | |
Total current liabilities | 260,631,960.02 | 261,994,738.06 | 1,362,778.04 |
Non-current liabilities: | |||
Long-term borrowings | |||
Debenture payables | |||
Including: Preference shares | |||
Perpetual bonds | |||
Lease liabilities | 1,773,784.94 | 1,773,784.94 | |
Long-term payables | |||
Long-term payroll payables | |||
Projected liabilities | |||
Deferred income | 14,107,308.34 | 14,107,308.34 | |
Deferred tax liabilities | 13,885,085.02 | 13,885,085.02 | |
Other non-current liabilities | |||
Total non-current liabilities | 27,992,393.36 | 29,766,178.30 | 1,773,784.94 |
Total liabilities | 288,624,353.38 | 291,760,916.36 | 3,136,562.98 |
Owners' equity (shareholders' | |||
equity): | |||
Paid-in capital (or share | 227,454,729.00 | 227,454,729.00 | |
capital) | |||
Other equity investments | |||
Including: Preference shares | |||
Perpetual bonds | |||
Capital reserves | 240,609,043.62 | 240,609,043.62 | |
Less: Treasury shares | 9,915,527.00 | 9,915,527.00 | |
Other comprehensive income | 44,578,088.09 | 44,578,088.09 | |
Special reserve | |||
Surplus reserve | 59,290,828.07 | 59,290,828.07 | |
Retained earnings | 412,122,217.11 | 411,762,545.25 | -359,671.86 |
Total Owners' equity (or | 974,139,378.89 | 973,779,707.03 | -359,671.86 |
shareholders' equity) | |||
Total liabilities and | 1,262,763,732.27 | 1,265,540,623.39 | 2,776,891.12 |
owners' equity (or | |||
shareholders' equity) | |||
- 37 -
Explanation of adjustment of each item:
- Applicable □ Not applicable
In December 2018, the Ministry of Finance of the People's Republic of China issued the Circular regarding Amendments on the PRC Accounting Standards for Business Enterprises No. 21 - Leases (Cai Kuai [2018] No. 35). Upon approval by the Board, the Company announced the adoption of above revised accounting standards in the Group commencing on January 1, 2021. Due to cumulative effect of the adoption, the Group adjusted the opening balance of retained earnings and the amounts of other related items in the financial statements at the beginning of the year (in which this standard was initially adopted). The data of comparable period shall not be adjusted.
- Explanation of first adoption of new leasing standards and comparative data of retrospective adjustment of the previous reporting period since 2021
- Applicable ✓ Not applicable
- Auditor's report
- Applicable ✓ Not applicable
- 38 -
Attachments
- Original document
- Permalink
Disclaimer
Joinn Laboratories China Co. Ltd. published this content on 30 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 April 2021 00:09:03 UTC.